GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
The $17 Billion Race: Why New Treatments for Alzheimer’s Disease Are Changing the Game
The fight against Alzheimer’s disease (AD) is entering a new, highly competitive phase, driven by recent scientific breakthroughs and a growing global market. While therapies targeting amyloid proteins have recently been validated, there remains a critical and ongoing unmet need for drugs that utilize alternative mechanisms of action. Experts are encouraged to see a broader range of therapeutic options emerging in the pipeline for patients.
Decoding the Latest Alzheimer's Setback: Why J&J’s "Failed" Drug Trial is Actually a Hidden Victory for Brain Science
When we think about the fight against Alzheimer’s disease, we often picture a coordinated, unstoppable march toward a cure led by massive organizations like the National Institute on Aging and the Alzheimer's Association.
"Lonely Waves" and Genetic Timers: The Latest Alzheimer’s Breakthroughs Decoded
If you opened Google Scholar or picked up the latest issues of Nature Neuroscience or The Lancet Neurology over the past few days, you would spot two huge themes: how our sleep architecture betrays early brain changes, and how combining blood tests with genetics creates an exact clock for when symptoms will start.
The Regulatory Shift: From Optional Inclusion to Mandatory Action
Learn how Glassbury AI bridges grassroots engagement and LLM companions to meet FDA Diversity Action Plan compliance and solve Alzheimer's trial enrollment.